Quantum Leap Healthcare Collaborative
search

Recent Results & Agents

Widely hailed as the future of phase II drug development, the adaptive I-SPY2 platform trial has set a new benchmark for efficiency, through innovation in trial design and clinical operations.

I-SPY 2 Agent Timeline

The I-SPY 2 TRIAL's ground-breaking adaptive, multi-agent design allows up to five agents (or combinations of agents) to be evaluated in parallel. Click on an agent of interest to view more information about the agent and the results from I-SPY 2.
Graduated Completed In Progress Halted TUCATINIB SD-101 + PEMBROLIZUMAB DURVALUMAB + OLAPARIB SGN-LIV1A PEMBROLIZUMAB x 8 PATRITUMAB
TALAZOPARIB + IRENOTECAN PEMBROLIZUMAB x 4 PLX3397 GANETESPIB TDM1 + PERTUZUMAB PERTUZUMAB
MK2206 GANITUMAB AMG 386 VELIPARIB + CARBOPLATIN NERATINIB CONTROL 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020

I-SPY2 Agents

The I-SPY2 Trial's ground-breaking adaptive, multi-agent design allows up to five agents (or combinations of agents) to be evaluated in parallel. Click on an agent of interest to view more information about the agent and the results obtained in I-SPY. Agents in the table below are ordered newest to oldest beast upon date of entry into the study.
Agent(s)
Status
Currently Enrolling
Currently Enrolling
Currently Enrolling
Currently Enrolling
Completed (Results Pending)
Completed (Results Pending)
Graduated
Halted for Toxicity
Stopped for Futility
Graduated
Graduated
Stopped for Futility
Stopped for Futility
Graduated
Graduated